Companies › CRISPR Therapeutics
4 active drug programs in 5 registered trials: 5 Phase 1; Hematology, Oncology, Cardiovascular, Immunology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CTX310 In vivo CRISPR-Cas9 gene editing targeting ANGPTL3 | ANGPTL3 | Phase 1 | Cardiovascular | Jun 2027 |
| CTX340 CRISPR-Cas9 therapy targeting angiotensinogen (AGT) gene disruption in liver | AGT | Phase 1 | Hypertension | Jul 2028 |
| CTX112 (Zugocabtagene geleucel, zugo-cel) CD19-directed CAR-T cell therapy; allogeneic T cells genetically modified using CRISPR-Cas | CD19 | Phase 1 | B-cell Lymphoma; Warm Autoimmune Hemolytic Anemia (WAIHA) | Jan 2030 |
| CTX112 CD19-directed allogeneic T-cell therapy with CRISPR-Cas9 gene editing | CD19 | Phase 1 | SLE (Systemic Lupus) | Dec 2031 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07491172 | CTX310 | Phase 1 | Cardiovascular | Metabolic and endocrine | Jun 2027 |
| NCT07758634 | CTX340 | Phase 1 | Hypertension | Cardiovascular | Jul 2028 |
| NCT05643742 | CTX112 (Zugocabtagene geleucel, zugo-cel) | Phase 1 | B-cell Lymphoma | Oncology | Jan 2030 |
| NCT06925542 | CTX112 | Phase 1 | SLE (Systemic Lupus) | Immunology | Dec 2031 |
| NCT07549698 | CTX112 (Zugocabtagene geleucel, zugo-cel) | Phase 1 | Warm Autoimmune Hemolytic Anemia (WAIHA) | Hematology | Dec 2033 |
Cash and short-term investments of $2.3bn on 2026-09-30; operating cash outflow about $379m a year; runway about 72 months at that burn, to Sep 2032
Press releases filed as 8-K in the last year:
Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.